文献速递外周动脉疾病

Passeo-18 Lux药物涂层球囊联合Pulsar-18裸金属支架治疗股腘动脉病变的12和24个月结果

Combining the Passeo-18 Lux Drug-Coated Balloon and the Pulsar-18 Bare Metal Stent: 12- and 24-Month Outcomes of the BIOLUX 4EVER Investigator-Initiated Trial.
PubMed 文献 · J Endovasc Ther · 2020-09-01

BIOLUX 4EVER试验前瞻性纳入120例股腘动脉病变患者,采用Passeo-18 Lux药物涂层球囊预扩张后植入Pulsar-18裸金属支架。12个月主要通畅率为89.9%(95%CI 84.0%-95.8%),24个月为83.5%(95%CI 89.9%-97.3%);免于靶病变血运重建率分别为93.6%和86.1%。结论认为该联合策略安全有效。

要点

  • 12个月主要通畅率89.9%,24个月83.5%,免于靶病变血运重建率分别为93.6%和86.1%。
  • 踝肱指数从基线0.68±0.09改善至12和24个月的0.93±0.11和0.93±0.12(p<0.001)。
  • 与仅用裸金属支架的前期4-EVER研究相比,药物涂层球囊预扩张可能提高1年和2年疗效。

核心结论

  • Passeo-18 Lux药物涂层球囊联合Pulsar-18裸金属支架治疗股腘动脉病变在24个月内安全有效。
  • 药物涂层球囊预扩张可能较单纯裸金属支架提高1年和2年疗效。

研究设计与样本

  • 前瞻性、多中心、研究者发起的BIOLUX 4EVER试验(NCT02211664),在比利时5个中心纳入120例有症状的股腘动脉原发病变患者。
  • 患者平均年龄70.9±10.5岁,79例男性;病变平均长度83.3±49.5 mm,平均参考血管直径5.26±0.59 mm。
  • 所有病变均接受Passeo-18 Lux药物涂层球囊治疗后植入Pulsar-18裸金属支架,随访至24个月。

主要发现

  • 12个月主要通畅率为89.9%(95%CI 84.0%-95.8%),24个月为83.5%(95%CI 89.9%-97.3%)。
  • 12个月和24个月免于靶病变血运重建率分别为93.6%(95%CI 89.9%-97.3%)和86.1%(95%CI 79.9%-92.3%)。
  • 试验期间10例患者死亡,均为非心血管原因,24个月生存率90.7%。
  • 踝肱指数从基线0.68±0.09改善至12和24个月的0.93±0.11和0.93±0.12(p<0.001);12个月时91/94例(96.8%)和24个月时78/83例(93.4%)Rutherford分级改善至少1级(p<0.001)。

临床怎么用

  • 对于股腘动脉原发病变,可考虑使用Passeo-18 Lux药物涂层球囊预扩张后植入Pulsar-18裸金属支架。
  • 该联合方案在24个月随访中显示出可接受的主要通畅率和免于靶病变血运重建率。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the outcomes after treating stenotic or occluded femoropopliteal lesions with a drug-coated balloon (DCB) followed by the implantation of a thin-strut self-expanding bare metal stent in the BIOLUX 4EVER trial (ClinicalTrials.gov identifier NCT02211664). MATERIALS AND METHODS: The prospective, multicenter, physician-initiated BIOLUX 4-EVER trial was conducted at 5 centers in Belgium and enrolled 120 patients (mean age 70.9±10.5 years; 79 men) with symptomatic stenotic or occluded de novo femoropopliteal lesions. A fifth of the patients had diabetes mellitus and nearly half had previous peripheral artery interventions. The lesions were a mean 83.3±49.5 mm long with a mean reference vessel diameter of 5.26±0.59 mm. Lesions were treated with a Passeo-18 Lux DCB followed by the implantation of a Pulsar-18 bare metal stent. Follow-up visits were conducted at 1, 6, 12, and 24 months postprocedure; the main outcome was primary patency at 12 months. RESULTS: Technical success was obtained in all patients. Primary patency was observed in 89.9% of patients (95% CI 84.0% to 95.8%) at 12 months and in 83.5% at 24 months (95% CI 89.9% to 97.3%), and freedom from target lesion revascularization was 93.6% (95% CI 89.9% to 97.3%) and 86.1% (95% CI 79.9% to 92.3%), respectively. Ten patients died throughout the course of the trial (90.7% survival at 24 months), all of noncardiovascular causes. The ankle-brachial index improved from 0.68±0.09 at baseline to 0.93±0.11 and 0.93±0.12 at 12- and 24-month follow-up visits (p<0.001). An improvement of at least 1 Rutherford category was observed in 91 of 94 patients (96.8%) at 12 months and 78 of 83 patients (93.4%) at 24 months (p<0.001). CONCLUSION: The combination of a Passeo-18 Lux DCB followed by a Pulsar-18 stent implantation produced safe and effective outcomes in the treatment of femoropopliteal lesions at up to 24 months. Adding paclitaxel to the bare nitinol stent platform by predilating with a Passeo-18 Lux DCB seems to increase efficacy at 1 and 2 years compared with the use of bare metal stents only, which were investigated in the precursor 4-EVER study.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Deloose K, Bosiers M, Peeters P, et al. Combining the Passeo-18 Lux Drug-Coated Balloon and the Pulsar-18 Bare Metal Stent: 12- and 24-Month Outcomes of the BIOLUX 4EVER Investigator-Initiated Trial. J Endovasc Ther. 2020. PMID: 32873131. doi:10.1177/1526602820952413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。